Navigation Links
Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
Date:9/28/2007

ROCHESTER, Minn., Sept. 28 /PRNewswire-USNewswire/ -- A Mayo Clinic review of patients' responses to a drug used to control nausea and vomiting during anesthesia for general surgery questions a U.S. Food and Drug Administration (FDA) warning against the drug's use. This study appears in the current issue of the journal Anesthesiology.

The FDA warning against droperidol was prompted in 2001 over concerns that the drug contributed to potentially fatal heart rhythm abnormalities. Mayo Clinic compared 139,932 patients' responses before the warning was issued (and droperidol was used) and found no proven cases of complications directly attributable to droperidol. In comparison, after the FDA warning, two of 151,256 patients had poor heart rhythm while receiving other, more expensive medication alternatives. The percentage of patients who received droperidol was 12 percent prior to the warning and 0 percent after placement of the warning.

Based on their findings, Mayo Clinic anesthesiologists conclude that the FDA warning against droperidol is unnecessary. They call for other investigators to study the topic to determine if further inquiry supports that conclusion.

"In our study, we obtained results that were just the opposite of what the FDA action would predict. We actually had fewer complications with droperidol," explains Gregory Nuttall, M.D., the lead Mayo Clinic anesthesiologist on the study. "In our experience, low-doses of droperidol used by a skilled team are the safer and more effective agent for controlling nausea and vomiting, which is why we are making plans to resume its low-dose use in select patients in the cardiac Intensive Care Unit."

Significance of the Mayo Clinic Study

The Mayo Clinic study is the first large, statistically well-controlled study of patient responses to droperidol at a single medical center over a long time (three years) that included treatment before and after the FDA warning. As such, it provides the strongest scientific evidence to date for the performance of droperidol and alternatives.

Background

Since the FDA warning about droperidol was issued in 2001, reports in medical literature have questioned its accuracy and usefulness. It has been well established that all drugs used to prevent or control nausea prior to anesthesia use in general surgery also can have the negative side effect of prolonging a particular kind of abnormal heart rhythm known as long QT. Practitioners didn't understand why just one drug was singled out for a warning.

Dr. Nuttall explains: "There is a basic question: Is droperidol really that bad when compared to all the other drugs? I worked with droperidol, and I never saw a problem at the low doses we are talking about. After the warning, we all went to the more expensive drugs. Then we encountered the problem that none address rescue therapy well -- that means once you're sick, you're stuck; the drugs don't work well. In addition, the data upon with the FDA based its decision came from case reports. Statistically, these are not as strong as controlled, systematic reviews of a large number of patient experiences at a single medical center using the same protocols."

Implications for Patient Care

The Mayo Clinic team hopes another large controlled study will determine if the Mayo results can be validated. If they are validated, it might then prompt the FDA to revoke the warning against droperidol.

In the meantime, Dr. Nuttall recommends that each institution approach low-dose droperidol use with caution in a heart-monitored setting and only with advice from highly trained and experienced anesthesiologists. "Our only interest here is in seeing that patients get the safest and most beneficial treatment," Dr. Nuttall says.

Collaboration and Support

In addition to Dr. Nuttall, other members of the Mayo Clinic study team include: Karen Eckerman, SRNA; Kelly Jacob, SRNA; Erin Pawlaski, SRNA; Susan Wigersma, SRNA; Mary Shirk Marienau, CRNA, MS; William Oliver, M.D.; Bradly Narr, M.D.; and Michael Ackerman, M.D., Ph.D. Support was provided by the Mayo Foundation for Medical Education and Research.


'/>"/>
SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... MEDsys ... Medicaid programs, Managed Care Organizations and Home Care Agencies, has been awarded CIO ... VinCENT, provides technology solutions to over 1,000 agencies and multiple State Medicaid and ...
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... ... 2017 , ... Healthy eating isn’t always easy. Currently, more than 80 percent of Americans fail ... overeat refined grains and sugar. This trend may help explain why the obesity rate seems ... obese. , As a culture, we seem to have food on the brain more. "We ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Freedom from ... startup companies around 117 breakthrough inventions from 55 institutions, including the National Institutes ... Institute of Biomedical Imaging and Bioengineering), the United States Army, and more than ...
(Date:7/27/2017)... ... ... Cremations recently surpassed traditional burials for the first time in the U.S. ... with over 70% of Americans projected to choose cremation by 2030. , In line ... to celebrate the life of a lost loved one in different ways using their ...
Breaking Medicine News(10 mins):